CA3160208A1 - High salt washes during cation exchange chromatography to remove product-realated impurities - Google Patents
High salt washes during cation exchange chromatography to remove product-realated impuritiesInfo
- Publication number
- CA3160208A1 CA3160208A1 CA3160208A CA3160208A CA3160208A1 CA 3160208 A1 CA3160208 A1 CA 3160208A1 CA 3160208 A CA3160208 A CA 3160208A CA 3160208 A CA3160208 A CA 3160208A CA 3160208 A1 CA3160208 A1 CA 3160208A1
- Authority
- CA
- Canada
- Prior art keywords
- sodium chloride
- wash buffer
- cation exchange
- acetate
- wash
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/424—Elution mode
- B01D15/426—Specific type of solvent
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/16—Diafiltration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Water Supply & Treatment (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962931874P | 2019-11-07 | 2019-11-07 | |
| US62/931,874 | 2019-11-07 | ||
| PCT/US2020/058774 WO2021091933A1 (en) | 2019-11-07 | 2020-11-04 | High salt washes during cation exchange chromatography to remove product-realated impurities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3160208A1 true CA3160208A1 (en) | 2021-05-14 |
Family
ID=73598212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3160208A Pending CA3160208A1 (en) | 2019-11-07 | 2020-11-04 | High salt washes during cation exchange chromatography to remove product-realated impurities |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220372071A1 (https=) |
| EP (1) | EP4055042A1 (https=) |
| JP (2) | JP2022554283A (https=) |
| KR (1) | KR20220092958A (https=) |
| CN (1) | CN114651007A (https=) |
| AR (1) | AR120398A1 (https=) |
| AU (1) | AU2020377919A1 (https=) |
| BR (1) | BR112022008782A2 (https=) |
| CA (1) | CA3160208A1 (https=) |
| CL (2) | CL2022001169A1 (https=) |
| IL (1) | IL292602A (https=) |
| MX (1) | MX2022005594A (https=) |
| TW (2) | TWI878377B (https=) |
| WO (1) | WO2021091933A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4263597A2 (en) * | 2020-12-18 | 2023-10-25 | Kiniksa Pharmaceuticals, Ltd. | Protein compositions and methods for producing and using the same |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9034298A (en) * | 1997-08-25 | 1999-03-16 | Walter H. Runkis | A simple, environmentally benign, method for purifying protein |
| ES2533266T5 (es) * | 2007-10-30 | 2018-04-18 | Genentech, Inc. | Purificación de anticuerpos mediante cromatografía de intercambio catiónico |
| US20120282654A1 (en) * | 2009-04-29 | 2012-11-08 | Schering Corporation | Antibody purification |
| WO2012125735A1 (en) * | 2011-03-15 | 2012-09-20 | Abott Laboratories | An integrated approach to the isolation and purification of antibodies |
| CN104628846B (zh) * | 2013-11-06 | 2019-12-06 | 三生国健药业(上海)股份有限公司 | 重组蛋白质的纯化方法 |
| WO2015198320A1 (en) * | 2014-06-24 | 2015-12-30 | Insight Biopharmaceuticals Ltd. | Methods of purifying antibodies |
| EP3177643B1 (en) * | 2014-08-04 | 2019-05-08 | F.Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
| EP3204415B1 (en) * | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| JP6699085B2 (ja) * | 2015-03-25 | 2020-05-27 | 東ソー株式会社 | Fc結合性タンパク質の精製方法 |
| EP4549463A3 (en) * | 2016-06-17 | 2025-07-30 | F. Hoffmann-La Roche AG | Purification of multispecific antibodies |
| JP2020525445A (ja) * | 2017-06-21 | 2020-08-27 | セファロン・インコーポレイテッドCephalon,Incorporated | カチオン交換クロマトグラフィーの洗浄緩衝液 |
| CN110305217B (zh) * | 2018-03-27 | 2022-03-29 | 广州爱思迈生物医药科技有限公司 | 双特异性抗体及其应用 |
-
2020
- 2020-11-04 BR BR112022008782A patent/BR112022008782A2/pt unknown
- 2020-11-04 MX MX2022005594A patent/MX2022005594A/es unknown
- 2020-11-04 EP EP20812495.8A patent/EP4055042A1/en active Pending
- 2020-11-04 CA CA3160208A patent/CA3160208A1/en active Pending
- 2020-11-04 US US17/773,892 patent/US20220372071A1/en active Pending
- 2020-11-04 IL IL292602A patent/IL292602A/en unknown
- 2020-11-04 WO PCT/US2020/058774 patent/WO2021091933A1/en not_active Ceased
- 2020-11-04 AU AU2020377919A patent/AU2020377919A1/en active Pending
- 2020-11-04 KR KR1020227018752A patent/KR20220092958A/ko active Pending
- 2020-11-04 JP JP2022525320A patent/JP2022554283A/ja active Pending
- 2020-11-04 CN CN202080077533.3A patent/CN114651007A/zh active Pending
- 2020-11-05 AR ARP200103071A patent/AR120398A1/es unknown
- 2020-11-06 TW TW109138883A patent/TWI878377B/zh active
- 2020-11-06 TW TW114107974A patent/TW202523676A/zh unknown
-
2022
- 2022-05-04 CL CL2022001169A patent/CL2022001169A1/es unknown
-
2024
- 2024-06-14 CL CL2024001792A patent/CL2024001792A1/es unknown
-
2025
- 2025-11-14 JP JP2025195036A patent/JP2026048656A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220372071A1 (en) | 2022-11-24 |
| CL2024001792A1 (es) | 2024-11-08 |
| IL292602A (en) | 2022-07-01 |
| BR112022008782A2 (pt) | 2022-07-26 |
| CL2022001169A1 (es) | 2023-01-27 |
| WO2021091933A1 (en) | 2021-05-14 |
| TW202132323A (zh) | 2021-09-01 |
| MX2022005594A (es) | 2022-06-09 |
| AR120398A1 (es) | 2022-02-09 |
| EP4055042A1 (en) | 2022-09-14 |
| TW202523676A (zh) | 2025-06-16 |
| JP2022554283A (ja) | 2022-12-28 |
| JP2026048656A (ja) | 2026-03-17 |
| KR20220092958A (ko) | 2022-07-04 |
| AU2020377919A1 (en) | 2022-06-16 |
| CN114651007A (zh) | 2022-06-21 |
| TWI878377B (zh) | 2025-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022523025A (ja) | 原薬及び製剤プロセスの統合による生物製剤製造のための連続的な製造プロセス | |
| WO2022072291A1 (en) | Cation exchange chromatography process | |
| US20230058276A1 (en) | Methods for harvesting biomolecules | |
| JP2026048656A (ja) | 生成物関連不純物を除去するためのカチオン交換クロマトグラフィー中の高塩分洗浄 | |
| US20240174752A1 (en) | Modulating product quality of asymmetric multispecific antibodies through the use of temperature | |
| US20260070943A1 (en) | A method for harvesting products from high cell density perfusion cell cultures | |
| JP7760500B2 (ja) | 生成物関連不純物を除去するためのカチオン交換クロマトグラフィー中の高塩分負荷コンディショニング | |
| EA046702B1 (ru) | Способы очистки биспецифических антител при помощи катионообменной хроматографии с использованием промывки с высоким содержанием соли | |
| EA047099B1 (ru) | Кондиционирование с высокой солевой нагрузкой в ходе катионообменной хроматографии для удаления связанных с продуктом примесей | |
| HK40070589A (en) | High salt washes during cation exchange chromatography to remove product-realated impurities | |
| HK40070045A (en) | High salt load conditioning during cation exchange chromatography to remove product-realated impurities | |
| WO2025251034A1 (en) | Purification method | |
| JP2026505293A (ja) | 細胞培養法 | |
| EA049616B1 (ru) | Непрерывный способ изготовления биопрепаратов посредством интеграции процессов получения лекарственного вещества и лекарственного препарата |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220823 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241104 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241104 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241104 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241113 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250313 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250314 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250606 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250606 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251022 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251022 |